Prior Authorizations: Where Are We and Where Can We Go? Observations from a working group of leaders in the oncology and payer space

Introduction Prior authorization of medical procedures, services, and medications have been a standard requirement for health care providers for decades. Rising health care costs, specifically the escalating cost of cancer drug therapies, have led to a renewed focus by payers, providers, and policy makers on prior authorization. Similarly, the challenges and frustrations of the

By |2022-12-27T14:44:53-05:00December 15th, 2021|Studies, Research & Publications|Comments Off on Prior Authorizations: Where Are We and Where Can We Go? Observations from a working group of leaders in the oncology and payer space

Letter to CMS on Step Therapy for Part B Drugs in Medicare Advantage

Dear Administrator Brooks-LaSure, The undersigned organizations, representing millions of Medicare beneficiaries with life-threatening, complex, chronic conditions and/or the physicians who care for them, are asking the Centers for Medicare and Medicaid Services (CMS) to ensure that beneficiaries enrolled in Medicare Advantage plans continue to have appropriate and timely access to the therapies they need

By |2022-09-01T13:22:40-04:00November 24th, 2021|Comment Letters|0 Comments

COA Letter to CMS and CMMI Requesting Extension of OCM

Dear Administrator Brooks-LaSure and Deputy Administrator Fowler: On behalf of the Board of Directors of the Community Oncology Alliance (“COA”), we are asking you to please extend the Oncology Care Model (“OCM”) past the scheduled termination date of June 30, 2022, and to announce this extension immediately.  As you know, the OCM starts winding

By |2022-12-27T14:28:17-05:00November 15th, 2021|Comment Letters|0 Comments

COA Comments on NCD for Next-Generation Sequence Comprehensive Genomic Profile Testing

Dear National Government Services Medical Policy Unit, On behalf of the Community Oncology Alliance (COA), we appreciate the opportunity to submit this public comment for the Proposed LCD - Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms (DL37810). COA is an organization dedicated to advocating for the complex care and access needs

By |2022-09-01T13:22:40-04:00November 15th, 2021|Comment Letters|0 Comments

COA CY 2022 OPPS Comment Letter

Dear Administrator Brooks-LaSure: On behalf of the Board of Directors of the Community Oncology Alliance (“COA”), we are submitting this comment letter regarding the CY 2022 Medicare Hospital Outpatient Prospective Payment System (“HOPPS”) Proposed Rule, Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs; Price Transparency of

By |2022-09-01T13:22:41-04:00September 17th, 2021|Comment Letters|0 Comments

Examining Hospital Price Transparency, Drug Profits, and the 340B Program 2021

Introduction The United States spends 17.7% of its GDP on health care related expenditures, far above its developed market peers, who generally spend no more than 12% of their GDP.  This excess health care spending added costs are an enormous burden on the U.S. economy and ‘crowd out’ important necessary spending on areas such

By |2022-12-27T14:23:13-05:00September 14th, 2021|Research & Publications, Studies|Comments Off on Examining Hospital Price Transparency, Drug Profits, and the 340B Program 2021

COA Formal Comments on 2022 Physician Fee Schedule

Dear Administrator Brooks-LaSure: On behalf of the Board of Directors of the Community Oncology Alliance (“COA”), we are submitting this comment letter regarding the CY 2022 Medicare Physician Fee Schedule Proposed Rule (“MPFS”, “the Proposed Rule”). As you know, COA is an organization dedicated to advocating for the complex care and access needs of

By |2022-09-01T13:22:41-04:00September 13th, 2021|Comment Letters|0 Comments

COA Letter on Cancer Care “Infrastructure” Crisis

Dear Majority Leader Schumer, Minority Leader McConnell, Speaker Pelosi, and Minority Leader McCarthy: On behalf of the Board of Directors of the Community Oncology Alliance (“COA”), we are writing to ask that you please help address the unfolding cancer care “infrastructure” crisis in this country and not make it worse with destructive policy and

By |2022-09-01T13:22:41-04:00September 8th, 2021|Comment Letters|0 Comments

COA COVID-19 Vaccinations and The Health Care Workforce Position Statement

With the recent surge in the COVID-19 Delta variant strain of the virus, the Board of Directors of the Community Oncology Alliance (COA) very strongly believes that all community oncology health care staff should be vaccinated.  How and if vaccinations are mandated, and how policies are implemented, including ongoing COVID testing, are obviously the

By |2022-09-01T13:30:44-04:00September 8th, 2021|Position Statements, Research & Publications|0 Comments

2021 Member Update

Dear COA Members and Supporters, The first half of 2021 has been a busy one. As the COVID-19 pandemic receded and vaccines succeeded, the Community Oncology Alliance (COA) worked diligently to ensure community oncology was prepared for the return of patients to waiting rooms and treatment facilities. At the same time, our advocacy efforts

By |2022-09-01T13:29:09-04:00August 19th, 2021|Annual & Mid-Year Reports, Member Updates|0 Comments